Proteomic approach to identify biomarkers for invasive cervix cancer - a prospective pilot study

D. Mysona, Adam Pyrzak, J. Allen, M. Powell, Daniel T Kleven, Wenbo Zhi, A. Sharma, S. Bai, Jin-Xiong She, Bunja Jane Rungruang, Sharad A Ghamande

Research output: Contribution to journalArticle

Abstract

Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors' objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9%, specificity 95%, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10-13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91-69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.

Original languageEnglish (US)
Pages (from-to)737-742
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume39
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Uterine Cervical Neoplasms
Proteomics
Biomarkers
Prospective Studies
Serum
Immunohistochemistry
Research Ethics Committees
Disease-Free Survival
Cell Biology
Blood Proteins
Neoplasms
Sensitivity and Specificity
Survival
Mortality

Keywords

  • Biomarkers
  • Cervical cancer
  • Serum proteomics

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Proteomic approach to identify biomarkers for invasive cervix cancer - a prospective pilot study. / Mysona, D.; Pyrzak, Adam; Allen, J.; Powell, M.; Kleven, Daniel T; Zhi, Wenbo; Sharma, A.; Bai, S.; She, Jin-Xiong; Rungruang, Bunja Jane; Ghamande, Sharad A.

In: European Journal of Gynaecological Oncology, Vol. 39, No. 5, 01.01.2018, p. 737-742.

Research output: Contribution to journalArticle

@article{367789e8d6c54617883cc3c93d5d7512,
title = "Proteomic approach to identify biomarkers for invasive cervix cancer - a prospective pilot study",
abstract = "Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors' objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9{\%}, specificity 95{\%}, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10-13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91-69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.",
keywords = "Biomarkers, Cervical cancer, Serum proteomics",
author = "D. Mysona and Adam Pyrzak and J. Allen and M. Powell and Kleven, {Daniel T} and Wenbo Zhi and A. Sharma and S. Bai and Jin-Xiong She and Rungruang, {Bunja Jane} and Ghamande, {Sharad A}",
year = "2018",
month = "1",
day = "1",
doi = "10.12892/ejgo4357.2018",
language = "English (US)",
volume = "39",
pages = "737--742",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "5",

}

TY - JOUR

T1 - Proteomic approach to identify biomarkers for invasive cervix cancer - a prospective pilot study

AU - Mysona, D.

AU - Pyrzak, Adam

AU - Allen, J.

AU - Powell, M.

AU - Kleven, Daniel T

AU - Zhi, Wenbo

AU - Sharma, A.

AU - Bai, S.

AU - She, Jin-Xiong

AU - Rungruang, Bunja Jane

AU - Ghamande, Sharad A

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors' objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9%, specificity 95%, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10-13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91-69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.

AB - Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors' objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9%, specificity 95%, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10-13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91-69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.

KW - Biomarkers

KW - Cervical cancer

KW - Serum proteomics

UR - http://www.scopus.com/inward/record.url?scp=85053324228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053324228&partnerID=8YFLogxK

U2 - 10.12892/ejgo4357.2018

DO - 10.12892/ejgo4357.2018

M3 - Article

AN - SCOPUS:85053324228

VL - 39

SP - 737

EP - 742

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 5

ER -